Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Mechanisms of resistance to decitabine in the myelodysplastic syndrome.

Qin T, Castoro R, El Ahdab S, Jelinek J, Wang X, Si J, Shu J, He R, Zhang N, Chung W, Kantarjian HM, Issa JP.

PLoS One. 2011;6(8):e23372. doi: 10.1371/journal.pone.0023372. Epub 2011 Aug 17.

2.

High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome.

Wu L, Shi W, Li X, Chang C, Xu F, He Q, Wu D, Su J, Zhou L, Song L, Xiao C, Zhang Z.

J Transl Med. 2016 Mar 5;14:66. doi: 10.1186/s12967-016-0817-9.

3.

The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome.

Wu P, Geng S, Weng J, Deng C, Lu Z, Luo C, Du X.

Leuk Res. 2015 Feb;39(2):216-20. doi: 10.1016/j.leukres.2014.08.016. Epub 2014 Sep 1.

PMID:
25533931
4.

Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment.

Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Köhler G, Wijermans P, Jones PA, Lübbert M.

Blood. 2002 Oct 15;100(8):2957-64.

5.

Digging deep into "dirty" drugs - modulation of the methylation machinery.

Pleyer L, Greil R.

Drug Metab Rev. 2015 May;47(2):252-79. doi: 10.3109/03602532.2014.995379. Epub 2015 Jan 8. Review.

6.

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.

Borthakur G, Ahdab SE, Ravandi F, Faderl S, Ferrajoli A, Newman B, Issa JP, Kantarjian H.

Leuk Lymphoma. 2008 Apr;49(4):690-5. doi: 10.1080/10428190701882146.

8.

Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome.

Yang Y, Zhang Q, Xu F, Chang C, Li X.

Eur J Haematol. 2012 Dec;89(6):469-77. doi: 10.1111/ejh.12014. Epub 2012 Oct 16.

PMID:
23005040
9.

In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.

Hackanson B, Robbel C, Wijermans P, Lübbert M.

Ann Hematol. 2005 Dec;84 Suppl 1:32-8. Review.

PMID:
16292549
12.

Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines.

Qin T, Jelinek J, Si J, Shu J, Issa JP.

Blood. 2009 Jan 15;113(3):659-67. doi: 10.1182/blood-2008-02-140038. Epub 2008 Oct 17.

13.

Methylation of the CpG island near SOX7 gene promoter is correlated with the poor prognosis of patients with myelodysplastic syndrome.

Fan R, Zhang LY, Wang H, Yang B, Han T, Zhao XL, Wang W, Wang XQ, Lin GW.

Tohoku J Exp Med. 2012 Jun;227(2):119-28.

15.

Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study.

Hatoum HT, Lin SJ, Buchner D, Kim E.

Curr Med Res Opin. 2011 Jun;27(6):1255-62. doi: 10.1185/03007995.2011.576236. Epub 2011 May 10.

PMID:
21554144
16.

TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes.

Chang CK, Zhao YS, Xu F, Guo J, Zhang Z, He Q, Wu D, Wu LY, Su JY, Song LX, Xiao C, Li X.

Br J Haematol. 2017 Feb;176(4):600-608. doi: 10.1111/bjh.14455. Epub 2016 Dec 16.

PMID:
27984642
17.

Decitabine treatment could ameliorate primary iron-overload in myelodysplastic syndrome patients.

Shucheng G, Chunkang C, Youshan Z, Juan G, Chengming F, Xi Z, Chao X, Xiao L.

Cancer Invest. 2015 Apr;33(4):98-106. doi: 10.3109/07357907.2014.1001895. Epub 2015 Feb 20.

PMID:
25699651
18.

Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?

Lowder JN, Taverna P, Issa JP.

Epigenomics. 2015 Oct;7(7):1083-8. doi: 10.2217/epi.15.66. Epub 2015 Nov 6. No abstract available.

PMID:
26541345
19.

Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.

Meldi K, Qin T, Buchi F, Droin N, Sotzen J, Micol JB, Selimoglu-Buet D, Masala E, Allione B, Gioia D, Poloni A, Lunghi M, Solary E, Abdel-Wahab O, Santini V, Figueroa ME.

J Clin Invest. 2015 May;125(5):1857-72. doi: 10.1172/JCI78752. Epub 2015 Mar 30.

20.

Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines.

Tsujioka T, Yokoi A, Uesugi M, Kishimoto M, Tochigi A, Suemori S, Tohyama Y, Tohyama K.

Exp Hematol. 2013 Feb;41(2):189-97. doi: 10.1016/j.exphem.2012.10.006. Epub 2012 Oct 17.

PMID:
23085465

Supplemental Content

Support Center